Medicare's projected $3.5 billion expenditure on Alzheimer’s drugs like Leqembi for 2025, as reported by STAT, has proven to be a significant overestimation. Actual spending is far lower, reflecting not just a forecasting error but a systemic failure in policy design, access mechanisms, and funding allocation for neurodegenerative diseases. This shortfall, while seemingly a financial reprieve for Medicare, masks a critical issue: limited patient access to novel treatments amid an aging population where Alzheimer’s prevalence is projected to rise from 6.7 million in 2023 to 13.8 million by 2060, per the Alzheimer’s Association. The original STAT coverage highlights the actuarial misstep but misses the broader implications for health equity and the structural barriers embedded in Medicare’s approach to specialty drugs.

First, let’s unpack the access issue. Leqembi, approved by the FDA in 2023, and Kisunla, another emerging therapy, are monoclonal antibodies targeting amyloid plaques in early-stage Alzheimer’s. Clinical trials, such as the CLARITY-AD study for Leqembi (RCT, n=1,795, published in NEJM 2023), showed a modest 27% reduction in cognitive decline over 18 months. However, Medicare’s coverage criteria remain restrictive, requiring registry enrollment and physician attestation of medical necessity, which disproportionately burdens rural and underserved populations with limited access to specialists. A 2022 observational study in JAMA Neurology (n=5,000) found that Black and Hispanic patients are 30% less likely to receive timely Alzheimer’s diagnoses, let alone access to cutting-edge treatments. STAT’s reporting overlooks how these coverage policies exacerbate existing disparities.

Second, the funding shortfall reflects a pattern of reactive rather than proactive policy-making for chronic diseases. Medicare’s hesitance to fully fund Alzheimer’s drugs mirrors historical underinvestment in other neurodegenerative conditions like Parkinson’s, where disease-modifying therapies remain scarce despite decades of research. The National Institute on Aging’s budget for Alzheimer’s research, while increased to $3.7 billion in 2023, still lags behind cancer ($7.3 billion), per NIH data, despite comparable societal costs—Alzheimer’s care costs the U.S. $345 billion annually, per the Alzheimer’s Association. This funding disparity signals a lack of urgency, which STAT fails to contextualize against the backdrop of an aging demographic crisis.

Third, conflicts of interest in drug pricing and lobbying cannot be ignored. Eisai, Leqembi’s manufacturer, has faced scrutiny for its pricing model ($26,500/year per patient) and aggressive lobbying for broader Medicare coverage, as noted in a 2023 Health Affairs analysis. STAT’s piece mentions lobbying but doesn’t connect it to the broader trend of pharmaceutical influence on policy, where drugmakers often prioritize profit over equitable distribution. This dynamic likely contributes to Medicare’s cautious spending but leaves patients caught in the crossfire.

Synthesizing these points, the shortfall isn’t just a numbers game—it’s a symptom of fragmented policy, entrenched inequities, and misaligned priorities. Beyond STAT’s focus on actuarial errors, the real story is how Medicare’s framework fails to anticipate the needs of a growing vulnerable population. If unaddressed, this gap risks widening disparities and delaying progress on neurodegenerative care at a time when innovation is finally gaining traction.